ATE221776T1 - Zusammensetzungen, die einen die mastzellendgranulation blockierenden h-1 rezeptorantagonisten als wirkstoff enthalten, für die behandlung von endogenen, schmerzhaften gastrointestinalen beschwerden nichtentzündlichen,nichtulzerativen ursprungs - Google Patents

Zusammensetzungen, die einen die mastzellendgranulation blockierenden h-1 rezeptorantagonisten als wirkstoff enthalten, für die behandlung von endogenen, schmerzhaften gastrointestinalen beschwerden nichtentzündlichen,nichtulzerativen ursprungs

Info

Publication number
ATE221776T1
ATE221776T1 AT95909451T AT95909451T ATE221776T1 AT E221776 T1 ATE221776 T1 AT E221776T1 AT 95909451 T AT95909451 T AT 95909451T AT 95909451 T AT95909451 T AT 95909451T AT E221776 T1 ATE221776 T1 AT E221776T1
Authority
AT
Austria
Prior art keywords
inflammatory
mast cell
blocking
endogene
treatment
Prior art date
Application number
AT95909451T
Other languages
English (en)
Inventor
Theoharis C Theoharides
Original Assignee
Kos Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kos Pharma Inc filed Critical Kos Pharma Inc
Application granted granted Critical
Publication of ATE221776T1 publication Critical patent/ATE221776T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95909451T 1994-02-09 1995-02-09 Zusammensetzungen, die einen die mastzellendgranulation blockierenden h-1 rezeptorantagonisten als wirkstoff enthalten, für die behandlung von endogenen, schmerzhaften gastrointestinalen beschwerden nichtentzündlichen,nichtulzerativen ursprungs ATE221776T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/193,597 US5648355A (en) 1994-02-09 1994-02-09 Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
PCT/US1995/001392 WO1995021611A2 (en) 1994-02-09 1995-02-09 Compositions comprising a mast cell degranulation-blocking agent for treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin

Publications (1)

Publication Number Publication Date
ATE221776T1 true ATE221776T1 (de) 2002-08-15

Family

ID=22714282

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95909451T ATE221776T1 (de) 1994-02-09 1995-02-09 Zusammensetzungen, die einen die mastzellendgranulation blockierenden h-1 rezeptorantagonisten als wirkstoff enthalten, für die behandlung von endogenen, schmerzhaften gastrointestinalen beschwerden nichtentzündlichen,nichtulzerativen ursprungs

Country Status (8)

Country Link
US (1) US5648355A (de)
EP (2) EP0748217B1 (de)
AT (1) ATE221776T1 (de)
AU (1) AU1741295A (de)
CA (1) CA2183069A1 (de)
DE (1) DE69527706T2 (de)
ES (1) ES2180626T3 (de)
WO (1) WO1995021611A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5888529A (en) * 1997-03-28 1999-03-30 The Regents Of The University Of California Ileus treatment method
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US20080153761A1 (en) * 1998-04-08 2008-06-26 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US6689748B1 (en) * 1998-04-08 2004-02-10 Theoharis C. Theoharides Method of treating mast cell activation-induced diseases with a proteoglycan
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US20050220909A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
US20040230559A1 (en) * 1999-08-09 2004-11-18 Mark Newman Information processing device and information processing method
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2003013245A1 (en) * 2001-08-07 2003-02-20 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
KR20040091014A (ko) * 2002-02-07 2004-10-27 위스콘신 얼럼나이 리서어치 화운데이션 항암 요법과 병행해서 사용하기 위한 폴리아민 화합물 및조성물
JP4500161B2 (ja) * 2002-04-30 2010-07-14 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
US20040127512A1 (en) * 2002-12-30 2004-07-01 Bradley Pharmaceuticals, Inc. Method of treating symptoms of non-constipated irritable bowel syndrome
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US20040266787A1 (en) * 2003-03-25 2004-12-30 Dr. Reddy's Laboratories Limited Novel amorphous form of [2-[4-[(4-chlorophenyl)-phenyl methyl]-1-piperazinyl]ethoxy]acetic acid and process for the preparation thereof
US20050020608A1 (en) * 2003-03-25 2005-01-27 Dr. Reddy's Laboratories Limited Crystalline cetirizine monohydrochloride
DK1624936T3 (da) 2003-05-16 2010-03-15 Univ Laval CNS-chloridmodulering og anvendelser deraf
US20050124965A1 (en) * 2003-12-08 2005-06-09 Becton, Dickinson And Company Phosphatase inhibitor sample collection system
US7923043B2 (en) * 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
WO2005110490A1 (en) * 2004-05-14 2005-11-24 Universite Laval Phospholipase c gamma modulation and uses thereof for management of pain and nociception
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
EP1895986A2 (de) * 2005-05-09 2008-03-12 Azur Pharma Formulierungen von mastzellen-stabilisierenden mitteln zur abgabe an das kolon
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US20070286892A1 (en) * 2006-06-13 2007-12-13 Uri Herzberg Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals
CN101484436A (zh) * 2006-06-15 2009-07-15 库多斯药物有限公司 作为parp抑制剂的2-氧基杂芳基酰胺衍生物
JP2009539963A (ja) * 2006-06-15 2009-11-19 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤
US20090209520A1 (en) * 2006-06-15 2009-08-20 Kudos Pharmaceuticals Limited 2 -oxybenzamide derivatives as parp inhibitors
TWI404716B (zh) * 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
TW200838534A (en) 2007-02-07 2008-10-01 Astellas Pharma Inc Treatment for irritable bowel syndrome
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
WO2008153761A1 (en) * 2007-05-23 2008-12-18 Mastcell Pharmaceuticals, Inc. Methods
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
AU2008299721A1 (en) 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
CN101821242B (zh) * 2007-10-17 2013-07-24 库多斯药物有限公司 4-[3-(4-环丙烷羰基-哌嗪-1-羰基)-4-氟-苄基]-2h-酞嗪-1-酮
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
CN102238945B (zh) * 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
TW201114756A (en) * 2009-07-15 2011-05-01 Astrazeneca Ab Phthalazinone compound
US9176146B2 (en) * 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
US9050275B2 (en) * 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
LT3003327T (lt) 2013-06-05 2017-12-27 Tricida Inc. Protonus surišantys polimerai, skirti geriamajam vartojimui
ES2857177T3 (es) 2014-12-10 2021-09-28 Tricida Inc Polímeros de unión de protones para administración oral
US20190209607A1 (en) 2016-05-06 2019-07-11 Tricida, Inc. Compositions for treating acid-base disorders
US11266684B2 (en) 2017-11-03 2022-03-08 Tricida, Inc. Compositions for and method of treating acid-base disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507321A (en) * 1982-02-17 1985-03-26 The Research Foundation Of State University Of New York Epithelial cell growth regulating composition containing polyamines and a method of using same
FR2630328B1 (fr) * 1988-04-22 1990-08-24 Inst Nat Sante Rech Med Derive de l'histamine, sa preparation et son application en therapeutique
US4843074A (en) * 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
NZ235877A (en) * 1989-11-02 1992-09-25 Mcneil Ppc Inc Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
US5250529A (en) * 1990-02-08 1993-10-05 Kos Pharmaceuticals, Inc. Method alleviating migraine headache with mast cell degranulation blocking agents
US5057322A (en) * 1990-08-10 1991-10-15 Baker Cummins Dermatologicals, Inc. Method of treating mast cell disease
NZ246748A (en) * 1991-12-27 1999-05-28 Kos Pharma Inc Migraine-preventing medicaments comprising a mast cell degranulation blocking agent (e.g. hydroxyzine, ketotifen, azatadine, azelastine, cyproheptadine, oxatomide, terfenadine, etc)

Also Published As

Publication number Publication date
EP1203586A3 (de) 2002-10-30
WO1995021611A3 (en) 1995-10-05
DE69527706D1 (de) 2002-09-12
AU1741295A (en) 1995-08-29
ES2180626T3 (es) 2003-02-16
EP0748217A1 (de) 1996-12-18
EP0748217B1 (de) 2002-08-07
CA2183069A1 (en) 1995-08-17
US5648355A (en) 1997-07-15
DE69527706T2 (de) 2002-11-28
WO1995021611A2 (en) 1995-08-17
EP1203586A2 (de) 2002-05-08

Similar Documents

Publication Publication Date Title
ATE221776T1 (de) Zusammensetzungen, die einen die mastzellendgranulation blockierenden h-1 rezeptorantagonisten als wirkstoff enthalten, für die behandlung von endogenen, schmerzhaften gastrointestinalen beschwerden nichtentzündlichen,nichtulzerativen ursprungs
KR970703172A (ko) 모노아민, 디아민, 티올-함유 금속 킬레이터(monoamine, diamide, thiol-containing metal chelating agents)
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
DE69511089D1 (de) Metalloproteinase-inhibitoren
TR199802273T2 (xx) Fibrotik lezyonlar�n onar�lmas� ve �nlenmesi.
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
ATE279919T1 (de) Agmatin für die behandlung neuropathischer schmerzen
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
RU94031161A (ru) Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
TW324662B (en) Benzamide-containing pharmaceutical composition
EA199900689A1 (ru) Атропизомеры 3-гетероарил-4(3h)-хиназолинонов для лечения нейродегенеративных и связанных с травмами цнс состояний
DE60210101D1 (de) Behandlung von haarfollikeln mit neurokinin 1 rezeptor antagonisten
DE60014343D1 (de) N-(2-phenyl-4-amino-butyl)-1-naphthamide als neurokinin-1 rezeptorantagonisten
DE69232516T2 (de) Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung
DE69731658D1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
ATE277926T1 (de) Trizyclische vasopressin agoniste
DE69731657D1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen
DE69526584T2 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
BR9903240A (pt) Composição farmacêutica para prevenção e tratamento de doenças de disfunção cognitiva num mamìfero
DE69426986T2 (de) Behandlung von laminitis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties